The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Special Committee

Update Released by Patheon’s Special Commmittee

Patheon’s Special Committee provided an update today:

“The Special Committee of Independent Directors of Patheon Inc. … today provided an update on its discussions with Lonza Group AG … regarding Lonza’s previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of the Company at a price of US$3.55 per share. The Special Committee also updated shareholders on Patheon’s litigation connected with the unsuccessful offer by JLL Patheon Holdings…”

You can check out the rest after the jump…

Monday Deal Review: April 6, 2009

One complex arrangement, two clinical trial updates, three commercial deals and other bits of Canadian deal and company miscellany after the jump…

Follow

Get every new post delivered to your Inbox.

Join 126 other followers